LILRB1/CD85j/ILT2 Protein, Rhesus macaque (440a.a, HEK293, Fc)

LILRB1/CD85j/ILT2 Protein is an inhibitory receptor broadly expressed on leukocytes and recognizes HLA-class I and human cytomegalovirus UL18^[1]. LILRB1/CD85j/ILT2 Protein, Rhesus macaque (440a.a, HEK293, Fc) is the recombinant Rhesus Macaque-derived LILRB1/CD85j/ILT2 protein, expressed by HEK293 , with C-hFc labeled tag.

LILRB1/CD85j/ILT2 Protein a member of the leukocyte immunoglobulin-like receptor (LIR) family which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs)^[2]. LILRB1/CD85j/ILT2 Protein is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity^[3].

Rhesus Macaque

HEK293

C-hFc

F7H3G7 (S17-H456)

692340  [NCBI]

Partial

Approximately 80-90 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

Greater than 95% as determined by Tris-Bis PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Kimiko Kuroki, et al. Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis. Hum Mol Genet. 2005 Aug 15;14(16):2469-80.  [Content Brief]

  [2]. Mi Deng, et al. Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antib Ther. 2021 Jan; 4(1): 16–33.

  [3]. Shannon M Kelley, et al. Putting the brakes on phagocytosis: “don’t-eat-me”signaling in physiology and disease. EMBO Rep. 2021 Jun 4;22(6):e52564.  [Content Brief]